Han Xiao

469 total citations
34 papers, 332 citations indexed

About

Han Xiao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Han Xiao has authored 34 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 11 papers in Surgery. Recurrent topics in Han Xiao's work include Prostate Cancer Treatment and Research (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Head and Neck Cancer Studies (5 papers). Han Xiao is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Head and Neck Cancer Studies (5 papers). Han Xiao collaborates with scholars based in United States, China and Canada. Han Xiao's co-authors include Dean F. Bajorin, Robert J. Motzer, Eric J. Sherman, Stephanie Smith–Marrone, Sofia Haque, George J. Bosl, David G. Pfister, Matthew G. Fury, James Spicer and Joseph M. Ferrara and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Oncologist.

In The Last Decade

Han Xiao

29 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Han Xiao United States	10	165	124	106	65	49	34	332
Yasuyoshi Sato Japan	11	102 0.6×	187 1.5×	63 0.6×	75 1.2×	36 0.7×	47	380
Whee-Sze Ong Singapore	5	98 0.6×	274 2.2×	144 1.4×	38 0.6×	33 0.7×	6	417
K. Matsuura Japan	12	246 1.5×	107 0.9×	121 1.1×	91 1.4×	59 1.2×	37	483
Piotr Skotnicki Poland	12	97 0.6×	135 1.1×	80 0.8×	51 0.8×	98 2.0×	31	392
Kenneth Hennrick United States	5	125 0.8×	66 0.5×	94 0.9×	78 1.2×	28 0.6×	10	356
D. Spielsinger United States	5	125 0.8×	268 2.2×	76 0.7×	23 0.4×	23 0.5×	11	352
Prakash Neupane United States	12	156 0.9×	324 2.6×	91 0.9×	100 1.5×	41 0.8×	37	466
Nhu Le Canada	6	175 1.1×	132 1.1×	92 0.9×	87 1.3×	57 1.2×	7	372
Rubén Olivares Chile	13	147 0.9×	103 0.8×	115 1.1×	41 0.6×	49 1.0×	33	383
Yu Yu Andreeva Russia	9	57 0.3×	127 1.0×	86 0.8×	118 1.8×	68 1.4×	70	351

Countries citing papers authored by Han Xiao

Since Specialization

Citations

This map shows the geographic impact of Han Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han Xiao more than expected).

Fields of papers citing papers by Han Xiao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Han Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han Xiao. The network helps show where Han Xiao may publish in the future.

Co-authorship network of co-authors of Han Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Han Xiao. A scholar is included among the top collaborators of Han Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Han Xiao. Han Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuang, Ming, et al.. (2025). Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial).. Journal of Clinical Oncology. 43(4_suppl). 570–570.

Autio, Karen A., Christos E. Kyriakopoulos, Han Xiao, et al.. (2025). A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes. Investigational New Drugs. 43(4). 924–932.

Das, Jeeban Paul, Thomas Powles, Dean F. Bajorin, et al.. (2024). Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4581–4581. 1 indexed citations

Qin, Shuai, Han Xiao, & Zhuying Li. (2023). Efficacy and safety of apatinib plus chemotherapy vs. chemotherapy alone for the treatment of advanced‑stage non‑small cell lung cancer: A meta‑analysis. Oncology Letters. 27(1). 25–25. 1 indexed citations

Kotecha, Ritesh R., Andrea Knežević, Joshua Chaim, et al.. (2023). A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. European Urology Oncology. 7(4). 804–811. 11 indexed citations

Romero, Sally A.D., Raymond E. Baser, Katherine S. Panageas, et al.. (2022). Acupuncture versus massage for pain in patients living with advanced cancer: a protocol for the IMPACT randomised clinical trial. BMJ Open. 12(9). e058281–e058281. 3 indexed citations

Zhang, Yang, Zongjuan Li, Han Xiao, et al.. (2022). Development and validation of a random forest model for predicting radiation pneumonitis in lung cancer patients receiving moderately hypofractionated radiotherapy: a retrospective cohort study. Annals of Translational Medicine. 10(23). 1264–1264. 7 indexed citations

Feldman, Darren R., Yasser Ged, Chung‐Han Lee, et al.. (2020). Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 126(24). 5247–5255. 27 indexed citations

Tao, Haitao, Fangfang Li, Ruixin Li, Han Xiao, & Yi Hu. (2020). Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report. Annals of Palliative Medicine. 9(5). 3623–3628. 4 indexed citations

10.

Xiao, Han, Yishu Tang, Qian Cheng, Jing Liu, & Xin Li. (2020). <p>Risk Prediction and Prognosis of Invasive Fungal Disease in Hematological Malignancies Patients Complicated with Bloodstream Infections</p>. Cancer Management and Research. Volume 12. 2167–2175. 11 indexed citations

11.

Liu, Juan, Yixing Chen, Han Xiao, et al.. (2019). <p>Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer</p>. Cancer Management and Research. Volume 11. 6029–6041. 6 indexed citations

12.

Morris, Michael J., Glenn Heller, Alan H. Bryce, et al.. (2019). Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(15_suppl). 5008–5008. 33 indexed citations

13.

Ma, Jennifer, Benjamin H. Lok, Jingfeng Zong, et al.. (2018). Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. International Journal of Particle Therapy. 4(4). 10–19. 9 indexed citations

14.

Aggarwal, Rahul, Scott E. Eggener, Ronald C. Chen, et al.. (2018). A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19).. Journal of Clinical Oncology. 36(15_suppl). TPS5090–TPS5090. 5 indexed citations

15.

Dunn, Lara, Nadeem Riaz, Shrujal S. Baxi, et al.. (2017). Phase Ib study of cetuximab + BYL719 + IMRT in stage III-IVB head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 35(15_suppl). 6081–6081. 3 indexed citations

16.

Xiao, Han, Zhao‐Chong Zeng, Zhiyong Xu, et al.. (2017). Constraints for symptomatic radiation pneumonitis of helical tomotherapy hypofractionated simultaneous multitarget radiotherapy for pulmonary metastasis from hepatocellular carcinoma. Radiotherapy and Oncology. 123(2). 246–250. 5 indexed citations

17.

Ho, Alan L., Eric J. Sherman, Han Xiao, et al.. (2014). A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. Investigational New Drugs. 32(3). 549–554. 3 indexed citations

18.

Fury, Matthew G., Eric J. Sherman, Neeraj Agarwal, et al.. (2012). A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m²for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 10(11). 1391–1398. 34 indexed citations

19.

Xiao, Han, David Liu, Dean F. Bajorin, Michael Burt, & George J. Bosl. (1998). MEDICAL AND SURGICAL MANAGEMENT OF PULMONARY METASTASES FROM GERM CELL TUMORS. Chest Surgery Clinics of North America. 8(1). 131–144. 6 indexed citations

20.

Xiao, Han, Madhu Mazumdar, Dean F. Bajorin, et al.. (1997). Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.. Journal of Clinical Oncology. 15(7). 2553–2558. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact